188 related articles for article (PubMed ID: 22387334)
1. Efficiency and risk factors for CMV transmission in seronegative hematopoietic stem cell recipients.
Pergam SA; Xie H; Sandhu R; Pollack M; Smith J; Stevens-Ayers T; Ilieva V; Kimball LE; Huang ML; Hayes TS; Corey L; Boeckh MJ
Biol Blood Marrow Transplant; 2012 Sep; 18(9):1391-1400. PubMed ID: 22387334
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation.
Lin TS; Zahrieh D; Weller E; Alyea EP; Antin JH; Soiffer RJ
Transplantation; 2002 Jul; 74(1):49-54. PubMed ID: 12134098
[TBL] [Abstract][Full Text] [Related]
3. Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease.
Bhutani D; Dyson G; Manasa R; Deol A; Ratanatharathorn V; Ayash L; Abidi M; Lum LG; Al-Kadhimi Z; Uberti JP
Biol Blood Marrow Transplant; 2015 Jan; 21(1):159-64. PubMed ID: 25445637
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus Infection Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation from a Single Institution.
Melendez-Munoz R; Marchalik R; Jerussi T; Dimitrova D; Nussenblatt V; Beri A; Rai K; Wilder JS; Barrett AJ; Battiwalla M; Childs RW; Fitzhugh CD; Fowler DH; Fry TJ; Gress RE; Hsieh MM; Ito S; Kang EM; Pavletic SZ; Shah NN; Tisdale JF; Gea-Banacloche J; Kanakry CG; Kanakry JA
Biol Blood Marrow Transplant; 2019 Mar; 25(3):577-586. PubMed ID: 30342913
[TBL] [Abstract][Full Text] [Related]
5. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis.
Ljungman P; Brand R; Einsele H; Frassoni F; Niederwieser D; Cordonnier C
Blood; 2003 Dec; 102(13):4255-60. PubMed ID: 12933590
[TBL] [Abstract][Full Text] [Related]
6. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients.
Zhou W; Longmate J; Lacey SF; Palmer JM; Gallez-Hawkins G; Thao L; Spielberger R; Nakamura R; Forman SJ; Zaia JA; Diamond DJ
Blood; 2009 Jun; 113(25):6465-76. PubMed ID: 19369230
[TBL] [Abstract][Full Text] [Related]
7. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
9. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation.
Nakamae H; Kirby KA; Sandmaier BM; Norasetthada L; Maloney DG; Maris MB; Davis C; Corey L; Storb R; Boeckh M
Biol Blood Marrow Transplant; 2009 Jun; 15(6):694-703. PubMed ID: 19450754
[TBL] [Abstract][Full Text] [Related]
10. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.
Boeckh M; Bowden RA; Storer B; Chao NJ; Spielberger R; Tierney DK; Gallez-Hawkins G; Cunningham T; Blume KG; Levitt D; Zaia JA
Biol Blood Marrow Transplant; 2001; 7(6):343-51. PubMed ID: 11464977
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis.
Boudreault AA; Xie H; Rakita RM; Scott JD; Davis CL; Boeckh M; Limaye AP
Transpl Infect Dis; 2011 Jun; 13(3):244-9. PubMed ID: 21414119
[TBL] [Abstract][Full Text] [Related]
12. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients.
Narvios AB; Przepiorka D; Tarrand J; Chan KW; Champlin R; Lichtiger B
Bone Marrow Transplant; 1998 Sep; 22(6):575-7. PubMed ID: 9758346
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus Infection after CD34(+)-Selected Hematopoietic Cell Transplantation.
Huang YT; Neofytos D; Foldi J; Kim SJ; Maloy M; Chung D; Castro-Malaspina H; Giralt SA; Papadopoulos E; Perales MA; Jakubowski AA; Papanicolaou GA
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1480-1486. PubMed ID: 27178374
[TBL] [Abstract][Full Text] [Related]
14. CMV mismatch does not affect patient and graft survival in UK renal transplant recipients.
Johnson RJ; Clatworthy MR; Birch R; Hammad A; Bradley JA
Transplantation; 2009 Jul; 88(1):77-82. PubMed ID: 19584684
[TBL] [Abstract][Full Text] [Related]
15. Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy.
Behrendt CE; Rosenthal J; Bolotin E; Nakamura R; Zaia J; Forman SJ
Biol Blood Marrow Transplant; 2009 Jan; 15(1):54-60. PubMed ID: 19135943
[TBL] [Abstract][Full Text] [Related]
16. Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study.
Narvios AB; Lichtiger B
Haematologica; 2001 Jul; 86(7):749-52. PubMed ID: 11454531
[TBL] [Abstract][Full Text] [Related]
17. Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME).
Thiele T; Krüger W; Zimmermann K; Ittermann T; Wessel A; Steinmetz I; Dölken G; Greinacher A
Transfusion; 2011 Dec; 51(12):2620-6. PubMed ID: 21645009
[TBL] [Abstract][Full Text] [Related]
18. The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT.
Schmidt-Hieber M; Tridello G; Ljungman P; Mikulska M; Knelange N; Blaise D; Socié G; Volin L; Blijlevens N; Fegueux N; Yakoub-Agha I; Forcade E; Maertens J; Chevallier P; Passweg J; Cornelissen J; Russell N; Craddock C; Bourhis JH; Marchand T; Reményi P; Cahn JY; Michallet M; Montoto S; Kröger N; Glaß B; Styczynski J
Ann Hematol; 2019 Jul; 98(7):1755-1763. PubMed ID: 30993417
[TBL] [Abstract][Full Text] [Related]
19. The clinical and economic impact of cytomegalovirus infection in recipients of hematopoietic stem cell transplantation.
Webb BJ; Harrington R; Schwartz J; Kammerer J; Spalding J; Lee E; Dodds B; Kaufusi S; Goodman BE; Firth SD; Martin G; Sorensen J; Hoda D
Transpl Infect Dis; 2018 Oct; 20(5):e12961. PubMed ID: 29975816
[TBL] [Abstract][Full Text] [Related]
20. Donor serostatus has an impact on cytomegalovirus-specific immunity, cytomegaloviral disease incidence, and survival in seropositive hematopoietic cell transplant recipients.
Ugarte-Torres A; Hoegh-Petersen M; Liu Y; Zhou F; Williamson TS; Quinlan D; Sy S; Roa L; Khan F; Fonseca K; Russell JA; Storek J
Biol Blood Marrow Transplant; 2011 Apr; 17(4):574-85. PubMed ID: 20688181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]